Anebulo pharmaceutical is a US small-cap ($80M market cap) biotech company that is developing a phase 2 asset for cannabis-related intoxication. ANEB-001 targets a cannabinoid intoxication; we do not ...
Anebulo Pharma (NASDAQ:ANEB) said on Thursday that it expects to release topline data from one part of its ongoing Phase 2 study of ANEB-001 to potentially treat acute cannabinoid intoxication (ACI) ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback